Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Sep 28

PMID 34575992

Citations 14

Authors

Monika Lejman

Kinga Kusmierczuk

Kinga Bednarz

Katarzyna Ostapinska

Joanna Zawitkowska

Affiliations

Soon will be listed here.

Abstract

Targeted therapy has revolutionized the treatment of poor-prognosis pediatric acute lymphoblastic leukemia (ALL) with specific genetic abnormalities. It is still being described as a new landmark therapeutic approach. The main purpose of the use of molecularly targeted drugs and immunotherapy in the treatment of ALL is to improve the treatment outcomes and reduce the doses of conventional chemotherapy, while maintaining the effectiveness of the therapy. Despite promising treatment results, there is limited clinical research on the effect of target cell therapy on the potential toxic events in children and adolescents. The recent development of highly specific molecular methods has led to an improvement in the identification of numerous unique expression profiles of acute lymphoblastic leukemia. The detection of specific genetic mutations determines patients' risk groups, which allows for patient stratification and for an adjustment of the directed and personalized target therapies that are focused on particular molecular alteration. This review summarizes the knowledge concerning the toxicity of molecular-targeted drugs and immunotherapies applied in childhood ALL.

Citing Articles

The role of GATA4 in mesenchymal stem cell senescence: A new frontier in regenerative medicine.

Babu M, S R, Kaur I, Kumar S, Sharma N, Kumar M Regen Ther. 2025; 28():214-226.

PMID: 39811069 PMC: 11731776. DOI: 10.1016/j.reth.2024.11.017.

Improving data interpretability with new differential sample variance gene set tests.

Rahmatallah Y, Glazko G Res Sq. 2024; .

PMID: 39315246 PMC: 11419169. DOI: 10.21203/rs.3.rs-4888767/v1.

Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).

Khawaji Z, Khawaji N, Alahmadi M, Elmoneim A Curr Treat Options Oncol. 2024; 25(9):1163-1183.

PMID: 39102166 DOI: 10.1007/s11864-024-01237-w.

A Second Wind for Inorganic APIs: Leishmanicidal and Antileukemic Activity of Hydrated Bismuth Oxide Nanoparticles.

Grafov A, da Silva Chagas A, de Freitas Gomes A, Ouedrhiri W, Cerruti P, Del Barone M Pharmaceutics. 2024; 16(7).

PMID: 39065571 PMC: 11279939. DOI: 10.3390/pharmaceutics16070874.

Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo.

Pasha F, Urbancic D, Maxhuni R, Krasniqi S, Grajcevci Uka V, Mlinaric-Rascan I Cancers (Basel). 2024; 16(11).

PMID: 38893109 PMC: 11171310. DOI: 10.3390/cancers16111988.

References

Millot F, Suttorp M, Versluys A, Kalwak K, Nelken B, Ducassou S . Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. Eur J Cancer. 2020; 136:107-112. DOI: 10.1016/j.ejca.2020.05.020. View

Garcia Borrega J, Godel P, Ruger M, Onur O, Shimabukuro-Vornhagen A, Kochanek M . In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere. 2019; 3(2):e191. PMC: 6746039. DOI: 10.1097/HS9.0000000000000191. View

Inaba H, Pui C . Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019; 38(4):595-610. PMC: 6995750. DOI: 10.1007/s10555-019-09834-0. View

Suryani S, Carol H, Chonghaile T, Frismantas V, Sarmah C, High L . Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014; 20(17):4520-31. PMC: 4154988. DOI: 10.1158/1078-0432.CCR-14-0259. View

August K, Guest E, Lewing K, Hays J, Gamis A . Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2019; 67(3):e28062. DOI: 10.1002/pbc.28062. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Grigor E, Fergusson D, Haggar F, Kekre N, Atkins H, Shorr R . Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open. 2017; 7(12):e019321. PMC: 5988064. DOI: 10.1136/bmjopen-2017-019321. View

Molina J, Shah N . CAR T cells better than BiTEs. Blood Adv. 2021; 5(2):602-606. PMC: 7839358. DOI: 10.1182/bloodadvances.2020003554. View

Parker K, Migliorini D, Perkey E, Yost K, Bhaduri A, Bagga P . Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020; 183(1):126-142.e17. PMC: 7640763. DOI: 10.1016/j.cell.2020.08.022. View

10.

Sentman M, Murad J, Cook W, Wu M, Reder J, Baumeister S . Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. J Immunol. 2016; 197(12):4674-4685. PMC: 5136298. DOI: 10.4049/jimmunol.1600769. View

11.

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

12.

Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P . Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019; 134(16):1351-1355. DOI: 10.1182/blood.2019001244. View

13.

Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

14.

Verstovsek S, Kantarjian H, Mesa R, Pardanani A, Cortes-Franco J, Thomas D . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. PMC: 5187954. DOI: 10.1056/NEJMoa1002028. View

15.

Iguchi A, Cho Y, Sugiyama M, Terashita Y, Ariga T, Hosoya Y . Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. Int J Hematol. 2017; 106(2):291-298. DOI: 10.1007/s12185-017-2235-z. View

16.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8):809-18. DOI: 10.1016/S1470-2045(14)70243-8. View

17.

Paul M, Mukhopadhyay A . Tyrosine kinase - Role and significance in Cancer. Int J Med Sci. 2005; 1(2):101-115. PMC: 1074718. DOI: 10.7150/ijms.1.101. View

18.

Leonard J, Rowley J, Eide C, Traer E, Hayes-Lattin B, Loriaux M . Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016; 8(354):354ra114. DOI: 10.1126/scitranslmed.aaf5309. View

19.

Tokarski J, Newitt J, Chang C, Cheng J, Wittekind M, Kiefer S . The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006; 66(11):5790-7. DOI: 10.1158/0008-5472.CAN-05-4187. View

20.

Shen S, Chen X, Cai J, Yu J, Gao J, Hu S . Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020; 6(3):358-366. PMC: 6990720. DOI: 10.1001/jamaoncol.2019.5868. View